Skip to content

Released May 8, 2023, before the open

10-Q filed May 8, 2023, 38 days after period end · 0001628280-23-016255

Q1 2023 · 10-Q
Revenue$5.31M+35.4% vs Q1 2022+26.9% vs Q4 2022
Net Income-$30.49MN/M vs Q1 2022N/M vs Q4 2022
EPS Diluted-$0.73N/M vs Q1 2022no prior Q4 2022 on file
Operating Income-$33,317,000N/M
Operating Cash Flow-$31,180,000N/M
Free Cash Flowderived-$31,816,000N/M
Margins · derived
Operating margin-627.6%+81.7 pt vs Q1 2022
Net margin-574.3%+112.3 pt vs Q1 2022

What the release said

The release

Same quarter

MetricQ1 2023Q1 2022Q1 2021Q1 2020
Revenue$5.31M$3.92M$286.00K$0.00
Net Income-$30.49M-$26.91M-$22.99M-$13.95M
EPS Diluted-$0.73-$0.65-$0.62-$2.71

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR